Journey Medical Corporation (DERM)
- Previous Close
3.5000 - Open
3.4900 - Bid 3.3600 x 100
- Ask 3.4800 x 100
- Day's Range
3.4050 - 3.5400 - 52 Week Range
1.0200 - 8.1100 - Volume
50,536 - Avg. Volume
169,917 - Market Cap (intraday)
68.168M - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2100 - Earnings Date May 20, 2024 - May 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.83
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
journeymedicalcorp.com41
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DERM
Performance Overview: DERM
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DERM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DERM
Valuation Measures
Market Cap
69.76M
Enterprise Value
57.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.85
Price/Book (mrq)
3.43
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
29.70
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.87%
Return on Assets (ttm)
0.74%
Return on Equity (ttm)
-20.64%
Revenue (ttm)
79.18M
Net Income Avi to Common (ttm)
-3.85M
Diluted EPS (ttm)
-0.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
27.44M
Total Debt/Equity (mrq)
87.12%
Levered Free Cash Flow (ttm)
-4.7M
Research Analysis: DERM
Company Insights: DERM
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: DERM
Daily – Vickers Top Buyers & Sellers for 03/26/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/18/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/11/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.